Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund named WSJ Category Kings

BOSTON, MA – (Marketwire, April 18, 2014) – The Eventide Gilead Fund (ETGLX) and the Eventide Healthcare & Life Sciences Fund (ETAHX) were both named “Category Kings” by the Wall Street Journal for the one-year period ending March 31, 2014. The award recognizes the top 10 funds in each category for total return for the one-year period. The Eventide Gilead Fund ranked #2 in Mid-Cap Growth out of 375 funds and the Eventide Healthcare & Life Sciences Fund ranked #6 in Health & Biotech out of 86 funds.

Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment advisor practicing values-based investing. Eventide CEO Robin John commented on the awards, “Eventide strives to invest in companies that not only excel at creating shareholder value – as the awards highlight – but also stakeholder value: for customers, employees, and society. We believe that by targeting companies focusing on broad stakeholder value creation, we have been able to generate this outperformance over the past year and since inception.”

Over the period, the Eventide Gilead Fund generated a total return of +44.36% compared to the Russell Mid-Cap Growth index return of +24.22% and the S&P 500 return of +21.86%, and outperformance of each by +20.14% and +22.5%, respectively; the Eventide Healthcare & Life Sciences Fund generated a total return of +49.11% compared to the Healthcare Blended Index of +32.44% and the S&P 500 return of +21.86%, an outperformance of each by +16.67% and +27.25%, respectively.

The following tables show the Funds’ performance since inception:

As of 3/31/2014 YTD return 1 year return 3 year annualized return 5 year annualized return Since inception (07/08/2008) annualized return
Eventide Gilead Fund* 6.59% 44.36% 21.48% 26.61% 18.24%
Russell Mid-Cap Growth Total Return Index 2.04% 24.22% 13.52% 24.73% 10.79%
S&P 500 Total Return Index 1.81% 21.86% 14.66% 21.16% 9.35%
As of 3/31/2014 YTD return 1 year return Since inception (12/27/2012) annualized return
Eventide Healthcare & Life Sciences Fund 8.87% 49.11% 57.25%
Healthcare Blended Index 0.53% 32.44% 40.04%
S&P 500 Total Return Index 1.81% 21.86% 27.37%

Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor’s shares, when redeemed, may be worth more or less than their original cost. Please review the funds’ prospectus for more information regarding the funds’ fees and expenses. Eventide Gilead Fund performance shown is for No-load Class shares and the Eventide Healthcare & Life Sciences Fund performance shown is for A Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month- end, please call toll-free 877-771-EVEN (3836).

Eventide Gilead Fund expenses: Gross Expenses 1.75%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund’s total annual operating expenses (excluding certain fees and expenses) at 1.42% at least until October 31, 2014. Eventide Healthcare & Life Sciences Fund expenses: Gross Expenses 9.56%; Net Expenses 1.69%. The advisor has agreed to maintain the Fund’s total annual operating expenses (excluding certain fees and expenses) at 1.43% at least until October 31, 2014.

As of March 31, 2014, the Eventide Gilead Fund had $630.2M in net assets and the Eventide Healthcare & Life Sciences Fund had $97.1M in net assets.

Wall Street Journal rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. The Eventide Gilead Fund ranked #9 out of 342 Mid-Cap Growth funds (Lipper data) for the 3-yr period based on total returns and #15 out of 288 Mid-Cap Growth funds (Lipper data) for the 5-yr period based on total returns.

The S&P 500 is an index created by Standard & Poor’s Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index. These indexes are not investment products available for purchase.

Mutual Funds involve risk including the possible loss of principal. The Eventide Funds can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The funds can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The funds can have risk associated with a higher portfolio turnover, which could result in higher transactional costs. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

An investor should consider the Funds’ investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about Eventide Funds can be found in the Funds’ prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836) or visit www.eventidefunds.com. Eventide Funds are distributed by Northern Lights Distributors, LLC, member FINRA, which is not affiliated with Eventide Asset Management, LLC.

Fund Contact:
Jason Myhre, 877-771-EVEN (3836)

4031-NLD-4/16/2014

News › Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund named WSJ Category Kings

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results.The Funds’ ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. Because of ongoing market volatility, the Funds performance may be subject to substantial short-term changes.

The Eventide Gilead Fund & Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector also carry various risks including, but not limited to, risk related to debt loads and intense competition.

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer-term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Fund’s portfolio may represent 0% to 100% of the Fund’s portfolio with an average duration of between two and eight years.

The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in “junk bonds.” Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, MLPs, preferred stocks, convertible bonds, BDCs, and yieldcos that are covered in the Fund's prospectus and SAI. The Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.